Sanofi (NASDAQ:SNY) Receives $49.50 Consensus Target Price from Analysts

Shares of Sanofi (NASDAQ:SNY) have been given a consensus recommendation of “Hold” by the fifteen ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, nine have given a hold rating, three have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $49.50.

A number of brokerages have recently issued reports on SNY. Morgan Stanley set a $49.00 target price on Sanofi in a research report on Wednesday, July 8th. Citigroup reissued a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. BNP Paribas Exane lowered Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research note on Monday, April 20th. Argus upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Finally, Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st.

Institutional Trading of Sanofi

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC increased its position in shares of Sanofi by 52.6% in the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after purchasing an additional 1,869 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Sanofi by 107.2% during the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after purchasing an additional 15,791 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Sanofi by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after purchasing an additional 752 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in Sanofi by 5.4% in the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after buying an additional 347 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in Sanofi by 36.1% in the second quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock valued at $159,000 after buying an additional 875 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Sanofi Price Performance

SNY opened at $43.46 on Monday. Sanofi has a twelve month low of $40.89 and a twelve month high of $52.68. The firm has a market cap of $105.37 billion, a price-to-earnings ratio of 22.75, a PEG ratio of 1.07 and a beta of 0.35. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21. The company has a fifty day simple moving average of $43.31 and a 200 day simple moving average of $45.06.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.